- 米国企業
- ADMA BIOLOGICS, INC.
ADMA BIOLOGICS, INC.ADMA
時価総額
$44.2億
PER
2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | |
NET LOSS | -7,301,313 | -15,527,246 | -16,813,163 | -17,969,930 | -19,515,151 | -43,758,975 | -65,743,445 | -48,279,317 | -75,748,548 | -71,647,618 | -65,903,950 | -28 |
Depreciation and amortization | 182,089 | 210,633 | 247,852 | 469,821 | 469,576 | 3 | 3 | 3 | 4 | 5 | 7 | 8 |
Loss on disposal of fixed assets | -18,399 | - | - | - | - | -10,144 | -122,190 | -207,071 | 81,697 | -220,761 | -426,536 | -0 |
Interest paid in kind | - | - | - | - | - | - | - | - | - | - | 3 | 4 |
Stock-based compensation | 626,787 | 888,295 | 1 | 2 | 1 | 2 | 2 | 3 | 3 | 3 | 5 | 6 |
Amortization of debt discount | 2,869 | 91,704 | 133,197 | 353,635 | 676,943 | 781,567 | 1 | 1 | 2 | 2 | 2 | 3 |
Loss on extinguishment of debt | - | - | - | -719,097 | - | -1,210,216 | - | -9,962,495 | 991,797 | - | -6,669,941 | -26 |
Amount of noncash revenue related to amortization of license revenue. | - | - | - | - | - | - | - | - | -142,834 | -142,834 | -142,834 | -0 |
Accounts receivable | -39,112 | 39,112 | 383,961 | 540,507 | 93,559 | 3 | -2,487,713 | 2 | -9,767,371 | 15 | -13,071,809 | 12 |
Inventories | 118,248 | 403,465 | 39,704 | 2 | 2 | -589,318 | 6 | 35 | -28,470,864 | 43 | 39 | 10 |
Prepaid expenses and other current assets | - | - | - | - | - | - | - | - | - | 1 | 755,900 | 0 |
Amount of increase (decrease) in deposits and operating assets classified as other. | - | - | - | - | - | - | - | - | - | 2 | -122,468 | -1 |
Accounts payable | -244,743 | 2 | -937,779 | 308,658 | 476,826 | 3 | -20,480 | 3 | 2 | 1 | 799,981 | 4 |
Accrued expenses | 150,622 | 76,471 | 1 | -199,615 | 416,972 | 614,483 | 406,984 | 806,353 | 3 | 8 | 8 | 8 |
Other current and non-current liabilities | - | - | - | - | - | - | 174,434 | -190,514 | - | 218,580 | -502,238 | -1 |
Net cash provided by (used in) operating activities | -6,903,795 | -10,887,154 | -14,704,910 | -15,418,404 | -18,268,973 | -37,271,774 | -62,678,682 | -76,193,504 | -102,002,958 | -112,368,982 | -59,508,257 | 9 |
Purchase of property and equipment | 118,853 | 196,635 | 2 | 26,073 | 73,410 | 3 | 2 | 4 | 13 | 14 | 14 | 5 |
Net cash used in investing activities | -118,853 | -3,131,819 | -4,040,743 | -1,741,575 | 904,583 | 15 | -2,095,600 | -3,811,838 | -12,724,680 | -13,511,258 | -13,911,171 | -5 |
Acquisition of intangible assets | - | - | - | - | - | - | - | - | - | - | - | 0 |
Net cash used in investing activities | -118,853 | -3,131,819 | -4,040,743 | -1,741,575 | 904,583 | 15 | -2,095,600 | -3,811,838 | -12,724,680 | -13,511,258 | -13,911,171 | -5 |
Principal payments on notes payable | 200,000 | - | - | 15 | - | 20 | - | 30 | - | - | 100 | 159 |
Proceeds from issuance of common stock, net of offering expenses | 17 | 27 | - | 10 | 14 | 39 | 43 | 48 | 131 | 121 | 65 | - |
The cash outflow for payment of debt refinancing fees. | - | - | - | - | - | - | - | - | -830,000 | - | 2 | 11 |
Proceeds from issuance of note payable | 4 | 1,000,000 | 10 | - | - | - | - | - | - | - | 152 | 135 |
Amount of cash outflow related to taxes on vested Restricted Stock Units. | - | - | - | - | - | - | - | - | - | 61,598 | 3 | 1 |
Payments on finance lease obligations | - | - | - | - | - | - | - | - | - | 34,299 | 36,684 | 0 |
Net proceeds from the exercise of stock options | - | - | - | 49,227 | - | 7,504 | 13,007 | 75,048 | 13,432 | - | 175,015 | 1 |
Payment of deferred financing fees | - | - | - | - | - | - | - | - | - | - | 3 | 2 |
Amount of cash outflow for end of term fee. | - | - | - | - | - | - | - | - | - | - | - | 2 |
Net cash (used in) provided by financing activities | 19 | 28 | 10 | 10 | 17 | 61 | 43 | 80 | 144 | 121 | 109 | -39 |
Payment of deferred financing fees | - | - | - | - | - | - | - | - | - | - | 3 | 2 |
Net cash (used in) provided by financing activities | 19 | 28 | 10 | 10 | 17 | 61 | 43 | 80 | 144 | 121 | 109 | -39 |
Net (decrease) increase in cash and cash equivalents | - | - | - | - | - | - | - | - | - | -4,832,034 | 35 | -35 |